EMPAREG Trial Randomised doubleblind placebocontrolled cardiovascular outcomes trial The primary end point is the time from randomization to a composite outcome consisting of the first occurrence of cardiovascular death nonfatal myocardial infarction or nonfatal stroke 3 point Major Advers ID: 774219
Download Presentation The PPT/PDF document "EMPA-REG Trial Randomised" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
EMPA-REG Trial Randomised , double-blind, placebo-controlled cardiovascular outcomes trial The primary end point is the time from randomization to a composite outcome consisting of the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (3 point Major Adverse Cardiovascular Events or 3-MACE)